Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

A. Nazha, M. Narkhede, T. Radivoyevitch, D. J. Seastone, B. J. Patel, A. T. Gerds, S. Mukherjee, M. Kalaycio, A. Advani, B. Przychodzen, H. E. Carraway, J. P. Maciejewski, M. A. Sekeres

Research output: Contribution to journalArticlepeer-review

Abstract

The Revised International Prognostic Scoring System (IPSS-R) was developed for untreated myelodysplastic syndrome (MDS) patients based on clinical data. We created and validated a new model that incorporates mutational data to improve the predictive capacity of the IPSS-R in treated MDS patients. Clinical and mutational data from treated MDS patients diagnosed between January 2000 and January 2012 were used to develop the new prognostic system. A total of 508 patients were divided into training (n=333) and validation (n=175) cohorts. Independent significant prognostic factors for survival included age, IPSS-R, EZH2, SF3B1 and TP53. Weighted coefficients for each factor were used to build the new linear predictive model, which produced four prognostic groups: low, intermediate-1, intermediate-2 and high with a median overall survival of 37.4, 23.2, 19.9 and 12.2 months, respectively, P<0.001. Significant improvement in the C-index of the new model (0.73) was observed compared with the IPSS-R (0.69). The new model predicted outcome both in a separate validation cohort and in another cohort of patients with paired samples at different time points during their disease course. The addition of mutational data to the IPSS-R makes it dynamic and enhances its predictive ability in treated MDS patients regardless of their initial or subsequent therapies.

Original languageEnglish (US)
Pages (from-to)2214-2220
Number of pages7
JournalLeukemia
Volume30
Issue number11
DOIs
StatePublished - Nov 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this